<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7D6D2169-850C-4CDC-B851-3A644DA28F85"><gtr:id>7D6D2169-850C-4CDC-B851-3A644DA28F85</gtr:id><gtr:name>University of Kentucky</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7D6D2169-850C-4CDC-B851-3A644DA28F85"><gtr:id>7D6D2169-850C-4CDC-B851-3A644DA28F85</gtr:id><gtr:name>University of Kentucky</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6B2DF52A-FCE9-4C50-B8A5-372AFE1D40DC"><gtr:id>6B2DF52A-FCE9-4C50-B8A5-372AFE1D40DC</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>O'Callaghan</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G116%2F165"><gtr:id>6DF2A95E-D33C-41BA-A692-EF1965565F4D</gtr:id><gtr:title>Distinguishing healthy and diseased cells for immune destruction: function and structure of MHC class I Homologues</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G116/165</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>I am studying the molecular mechanisms by which diseased cells identify themselves to the immune system for destruction. Rapid destruction of diseased cells is essential if tumour cells are not to proliferate into cancers and if pathogen-infected cells are not to spread their infections to other cells. Adaptive or ?learnt? immunity can be effective, but takes time to develop. In contrast, natural killer cells can rapidly destroy diseased cells. Diseased cells send molecules to their surfaces which act as flags to identify them as diseased to natural killer cells. The importance of natural killer cell recognition is highlighted by recent observations that viruses such as cytomegalovirus, have evolved multiple mechanisms to evade them.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1182393</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Birmingham Cancer Research UK Centre</gtr:department><gtr:description>Collaboration with Professor Paul Moss</gtr:description><gtr:id>932F9D9E-B168-4769-AFA6-92E2DA49FEFF</gtr:id><gtr:impact>Paper : PMID 20219610</gtr:impact><gtr:outcomeId>782453DC256-1</gtr:outcomeId><gtr:piContribution>We have provided structural data about the NKG2D ligands and structural models of allelic variations that may affect the ligand-receptor interactions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Metabolites and innate immune cell recognition with SS</gtr:description><gtr:id>2B328B58-4A6E-42B8-9549-FB2E8AF407AE</gtr:id><gtr:impact>none yet.</gtr:impact><gtr:outcomeId>58754a02c06f29.69598174-1</gtr:outcomeId><gtr:partnerContribution>shared experiments, expertise and reagents</gtr:partnerContribution><gtr:piContribution>Collaboration on innate immune cell recognition mechanisms and metabolism.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Metabolites and immune cell function with CM, TS and others</gtr:description><gtr:id>B69B5648-C6B5-48D8-A3DE-1E21C8B7550A</gtr:id><gtr:impact>none yet.</gtr:impact><gtr:outcomeId>58754acbcbb126.52272991-1</gtr:outcomeId><gtr:partnerContribution>shared experimental protocols, reagents, exchange visits and projects.</gtr:partnerContribution><gtr:piContribution>shared experimental protocols, reagents, exchange visits and projects.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Collaboration with Professor Steve Watson</gtr:description><gtr:id>927106CE-A806-4AB8-A653-6BDFF2A48DF6</gtr:id><gtr:impact>Publications - PMID 18215137, PMID 20154219</gtr:impact><gtr:outcomeId>05B33D25720-1</gtr:outcomeId><gtr:partnerContribution>Help with platelet studies.</gtr:partnerContribution><gtr:piContribution>We have identified and crystallized a novel receptor which promotes platelet activation and aggregation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Cellular and Molecular Physiology (CCMP)</gtr:department><gtr:description>Natural killer cell assays</gtr:description><gtr:id>D0E8B403-B5F1-4F49-855F-CBB039013AD0</gtr:id><gtr:impact>Paper PMID 20967261</gtr:impact><gtr:outcomeId>g5x6ihQpvUB-1</gtr:outcomeId><gtr:partnerContribution>help with staffing</gtr:partnerContribution><gtr:piContribution>Developing a flow cytometry-based assay for routine clincal assessment of natural killer cell function.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Kentucky</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Collaboration with Professor Andrew Morris</gtr:description><gtr:id>C85286D7-3F5D-4228-AC2A-323A39FA8D71</gtr:id><gtr:impact>manuscripts in preparation</gtr:impact><gtr:outcomeId>s3LZCybgDbD-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided us with some help on lipid component characterisation and quantification.</gtr:partnerContribution><gtr:piContribution>We have developed assays of macrophages and their lipid metabolism relevant to atherosclerosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Structural Biology</gtr:department><gtr:description>Hedgehog protein studies</gtr:description><gtr:id>71178F7E-6768-49ED-A7CD-3C8AFBA491E2</gtr:id><gtr:impact>Publications PMID 19561611</gtr:impact><gtr:outcomeId>F89B9C83D64-1</gtr:outcomeId><gtr:partnerContribution>Expertise in hedgehog ligand biology</gtr:partnerContribution><gtr:piContribution>Expertise in the analysis of protein-protein interactions using surface plasmon resonance and isothermal titration microcalorimetry.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Immunometabolism collaborative consortium</gtr:description><gtr:id>903065BB-0146-4E99-ADAD-B079DB6A893E</gtr:id><gtr:impact>a major 40 million DK grant</gtr:impact><gtr:outcomeId>56df4de2c27be5.05093733-1</gtr:outcomeId><gtr:partnerContribution>major scientific and intellectual input to the project.</gtr:partnerContribution><gtr:piContribution>I am a co-applicant on a major consortium grant and am leader of one of the three workstreams.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient participation in research event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7689FABB-928C-421B-88E8-2900E35D299B</gtr:id><gtr:impact>talks and small group workshops

Real help in designing the research.</gtr:impact><gtr:outcomeId>54628af2bbfbc0.34140678</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4BEDC5CD-2262-4E81-8E70-5F9829798AAF</gtr:id><gtr:impact>Our website provides information to the public about our research activities.

I have received questions from the public.</gtr:impact><gtr:outcomeId>A5C0F31ABDE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ccmp.ox.ac.uk/o-callaghan-group</gtr:url><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit - oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F13888D8-F4D0-4E77-BEB1-1C3864E408AD</gtr:id><gtr:impact>50+ pupils attended a talk which generated lots of questions and interest in the research.

sixth formers expressed interest in research as a career</gtr:impact><gtr:outcomeId>F5kzbVRsnBA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC PhD Studentship</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E35B2018-95C2-44E7-A2A6-381C3E5691DA</gtr:id><gtr:outcomeId>ED61EC0B4090</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Prize Studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Joyce Frankland Trust</gtr:fundingOrg><gtr:id>CBC1B0F8-AEAD-47CB-BD03-A4400E3E0867</gtr:id><gtr:outcomeId>56df4aae32e973.50037054</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:end>2009-11-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>E71FF944-F8AF-43F4-B0C4-F4E09E0B4690</gtr:id><gtr:outcomeId>2EC53B80DAA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>176940</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF project grant</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>1ADCD0E0-62B7-4F53-9567-05EE3B954429</gtr:id><gtr:outcomeId>ejiZU95nPJq0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clarin Postdoctoral Fellowship</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>Foundation for the Promotion of Applied Scientific Research and Technology in Asturias</gtr:fundingOrg><gtr:id>9C5B776E-DCF1-4E4A-AC2E-22013E892D5F</gtr:id><gtr:outcomeId>0B4FA5C5C590</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European Foundation for the Study of Diabetes (EFSD)</gtr:department><gtr:description>European Foundation for the Study of Diabetes/JDRF European Programme in type 1 diabetes research</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>European Association for the Study of Diabetes (EASD)</gtr:fundingOrg><gtr:fundingRef>96111</gtr:fundingRef><gtr:id>821158AA-E112-401E-A9D9-C92A154DC65F</gtr:id><gtr:outcomeId>58754c08e26b53.10379064</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185970</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Training Fellowship for Michael McCarthy</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0D65CCBE-0C2B-4320-8FC2-475D80D175CC</gtr:id><gtr:outcomeId>fBcoxiHaPwU0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>Panama, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Panamanian research studentship</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Government of the Republic of Panama</gtr:fundingOrg><gtr:id>3C7E87F9-A83C-4E82-A0F6-A5BE29A5F7A9</gtr:id><gtr:outcomeId>A02A5AA4BB20</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244488</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust clinical training fellowship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>0D38E0A0-FDC7-4952-A53E-86735D8DB324</gtr:id><gtr:outcomeId>54536a1d0245a2.55630210</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000000</gtr:amountPounds><gtr:country>Denmark, Kingdom of</gtr:country><gtr:currCode>DKK</gtr:currCode><gtr:currCountryCode>Denmark</gtr:currCountryCode><gtr:currLang>da_DK</gtr:currLang><gtr:department>Novo Nordisk Foundation</gtr:department><gtr:description>Novo Nordisk Fonden Collaborative Grant</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Novo Nordisk</gtr:fundingOrg><gtr:id>823F38F2-564B-43F2-9633-BBDE825DCCE5</gtr:id><gtr:outcomeId>56df4a544e3c97.62350171</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:fundingRef>15/0005171</gtr:fundingRef><gtr:id>7C5C12E5-4862-4AF6-ABBC-01E5085F1292</gtr:id><gtr:outcomeId>56df4b6902c814.73885070</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>51960</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Research Capability Funding (RCF)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>RCf121377</gtr:fundingRef><gtr:id>34023478-38DA-4189-B5B2-937A358F7981</gtr:id><gtr:outcomeId>axm4Xd2qYeA</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UK Government Overseas Research Studentship</gtr:description><gtr:end>2008-10-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>60490556-D3CF-4CBB-B135-ABC87B6C6C64</gtr:id><gtr:outcomeId>5799A2870B50</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17360</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Renal Society</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>British Renal Society</gtr:fundingOrg><gtr:fundingRef>11-007</gtr:fundingRef><gtr:id>D2F2B697-D5BC-4E0E-B435-3F673E053763</gtr:id><gtr:outcomeId>nPwMCWQVPuv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>226021</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust clinical research training fellowhsip</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>DB0909CB-0677-446C-938A-CCC1DC78330E</gtr:id><gtr:outcomeId>XRB2vDkGbEn0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UKCRN/TVCLRN NHS R and D</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4B3F221A-0605-4176-BE40-D9ED7AB6FD47</gtr:id><gtr:outcomeId>7B3469F3B9A0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>45000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Centenary early career award for michael mccarthy</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D80CBB0B-81A2-4ACD-952F-DF4BC44FD119</gtr:id><gtr:outcomeId>546288427e7480.04942001</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>423781</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Veterinary Postdoctoral Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>99EED821-2454-4410-877D-22AE1DBB0FB7</gtr:id><gtr:outcomeId>iNyFhmeMKP20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>244488</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Research Training Fellowship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>3BB5E376-50C1-422F-A209-121B3566C13A</gtr:id><gtr:outcomeId>LZRkz9W3iz6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>PROBLEM TO BE SOLVED: To provide a method for preventing inhibition of NK cell activity mediated by HLA-E. ; SOLUTION: The method for preventing inhibition of NK cell activity mediated by HLA-E, includes (a) selecting a compound that interferes with the binding of HLA-E to an inhibitory CD94/NKG2 receptor and (b) bringing an NK cell or T cell expressing the inhibitory CD94/NKG2 receptor into contact with the compound.</gtr:description><gtr:grantRef>G116/165</gtr:grantRef><gtr:id>719743DC-98C1-4DB0-95BD-D5770819792E</gtr:id><gtr:impact>High level publication in various journals. 
Patent granted in US, Europe and Japan.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>DntA6RQtjkw</gtr:outcomeId><gtr:patentId>WO9928748</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>HLA-E Binding</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National UKCRN renal specialty committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8BEEAE59-ED9D-4B48-9A91-1FBF9BE83855</gtr:id><gtr:outcomeId>ocmmfir6Cbm</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The OxCKD1 trial is testing the value of a comprehensive range of interventions to help people reduce their dietary salt intake. This includes the use of technology to prompt and promote healthy choices.</gtr:description><gtr:id>58991CD2-E70B-4316-94AC-0513A437F590</gtr:id><gtr:impact>The trial is still ongoing.</gtr:impact><gtr:outcomeId>54536b3a140562.39191190</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>OxCKD1- Empowering healthy lifestyle choices.</gtr:title><gtr:type>Therapeutic Intervention - Psychological/Behavioural</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A technology for the production and application of BirA ( a biotinylating protein) that allows this enzyme to be used to place a biotin molecule on a defined portion of a protein. This allows the protein to be tethered to fluorescently labeled streptavidin derivates. As each streptavidin molecule binds four biotin molecues, a species is created which is tetrameric with respect to the labeled protein. The fluorescent tetrameric protein can then be used in flow cytometry. We further developed this approach</gtr:description><gtr:id>C767C1B5-9972-4E79-ACB5-8A4CA0A9C6E7</gtr:id><gtr:impact>A great enhancement in the precision and quality of binding data obtained using surface plasmon resonance.</gtr:impact><gtr:outcomeId>BFB7FFD04BF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Orientated coupling to biosensor surfaces</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>an antibody was generated to a novel innate immune receptor</gtr:description><gtr:id>3A8738CF-A68B-4A62-A738-554DE90E9B6E</gtr:id><gtr:impact>identification of cells expressing it and their potential disease role</gtr:impact><gtr:outcomeId>C6F40584D84</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>antibody to innate immune receptor 1</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A set of around 1000 plasmids for expression or manipulation of innate immune ligands and receptors.</gtr:description><gtr:id>E95CE68C-7D13-48DC-86C2-F3A32C474368</gtr:id><gtr:impact>Publications as listed elsewhere.</gtr:impact><gtr:outcomeId>73FAA23E3C9</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>plasmids</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>an antibody was generated to a novel innate immune receptor</gtr:description><gtr:id>69C38F3D-A6A5-459B-896B-FD1873BAF142</gtr:id><gtr:impact>identification of expression of this receptor and studies of its function.</gtr:impact><gtr:outcomeId>C3BCA50FE5C</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>antibody to innate immune receptor 2</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>X-ray crystallographic structures. The co-ordinates are deposited in the PDB public database</gtr:description><gtr:id>F31730F3-A978-43AA-8683-6F86407BF722</gtr:id><gtr:impact>The structures can now being used for structure based drug design.</gtr:impact><gtr:outcomeId>4113EF263B6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Protein structures</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A web-based tool for the design of molecular biology cloning experiments and the analysis of nucleic acid sequences. Usable on any platform.</gtr:description><gtr:id>D53BFA2B-7997-4759-B705-8C5D0BFEE31D</gtr:id><gtr:impact>We have had positive feed back from other groups on this improved version of our previous DNA analysis tool.</gtr:impact><gtr:outcomeId>3DEB37A14BF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Web-based sequence analysis and manipulation tool</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Solid-phase plate-reader quantification of specific PCR products by measurement of band-specific ethidium bromide fluorescence.</gtr:description><gtr:id>26ADEADE-1049-4B15-8E1B-AD24E16DD3AA</gtr:id><gtr:impact>Publication of an article in the premier methodology journal Analytical Biochemistry.</gtr:impact><gtr:outcomeId>54536baf134cc2.51352494</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Quantitation of transcripts</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.sciencedirect.com/science/article/pii/S0003269713005290</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Development of an algorithm and software to identify peaks in high throughput sequencing data and to allow comparison between datasets with differing signal to noise ratios.</gtr:description><gtr:id>E1924EDB-B46D-456B-A974-7AFB02A91657</gtr:id><gtr:impact>Publication currently pending. This software has been used to analyse and compare datasets that might not otherwise be useful.</gtr:impact><gtr:outcomeId>jhi5EsJCq4S</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Peak identification algorithm and software</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:url>http://www.ccmp.ox.ac.uk/o-callaghan-group</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>Hypersensitivity to DNaseI digestion is a hallmark of open chromatin, and DNaseI-seq allows the genome-wide identification of regions of open chromatin. Interpreting these data is challenging, largely because of inherent variation in signal-to-noise ratio between datasets. We have developed PeaKDEck, a peak calling program that distinguishes signal from noise by randomly sampling read densities and using kernel density estimation to generate a dataset-specific probability distribution of random background signal. PeaKDEck uses this probability distribution to select an appropriate read density threshold for peak calling in each dataset. We benchmark PeaKDEck using published ENCODE DNaseI-seq data and other peak calling programs, and demonstrate superior performance in low signal-to-noise ratio datasets.</gtr:description><gtr:id>7EEF371E-A6FA-43AC-9FD0-D2DB5A312290</gtr:id><gtr:impact>We have had a number of emails from workers around the world who are using the software and have used it ourselves to analyse high throughput sequencing data.</gtr:impact><gtr:outcomeId>5453682fa92bc3.38584401</gtr:outcomeId><gtr:title>PeaKDEck: a kernel density estimator-based peak calling program for DNaseI-seq data</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.ccmp.ox.ac.uk/peakdeck</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>Minimization is a valuable method for allocating participants between the control and experimental arms of clinical studies.
The use of minimization reduces differences that might arise by chance between the study arms in the distribution of
patient characteristics such as gender, ethnicity and age. However, unlike randomization, minimization requires real time
assessment of each new participant with respect to the preceding distribution of relevant participant characteristics within
the different arms of the study. For multi-site studies, this necessitates centralized computational analysis that is shared
between all study locations. Unfortunately, there is no suitable freely available open source or free software that can be
used for this purpose. OxMaR was developed to enable researchers in any location to use minimization for patient allocation
and to access the minimization algorithm using any device that can connect to the internet such as a desktop computer,
tablet or mobile phone. The software is complete in itself and requires no special packages or libraries to be installed. It is
simple to set up and run over the internet using online facilities which are very low cost or even free to the user.
Importantly, it provides real time information on allocation to the study lead or administrator and generates real time
distributed backups with each allocation. OxMaR can readily be modified and customised and can also be used for standard
randomization. It has been extensively tested and has been used successfully in a low budget multi-centre study. Hitherto,
the logistical difficulties involved in minimization have precluded its use in many small studies and this software should
allow more widespread use of minimization which should lead to studies with better matched control and experimental
arms. OxMaR should be particularly valuable in low resource settings.</gtr:description><gtr:id>9FFD36B7-170D-443E-A956-4D6C4D024694</gtr:id><gtr:impact>The software has already been used successfully in one clinical trial - OxCKD1 which has now completed recruitment and is in the follow up phase.</gtr:impact><gtr:outcomeId>545367a099d588.71118206</gtr:outcomeId><gtr:title>OxMaR: Open Source Free Software for Online</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://sourceforge.net/projects/oxmar/</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>Development of robust bioinformatic tools to analyse next generation sequencing data across the whole genome and establish the impact of metabolite signalling on the transcriptome and on the epigenetics status of the cell and chromatin.</gtr:description><gtr:id>F44F5937-3C90-4ACD-BC3E-4A6CFD1F3026</gtr:id><gtr:impact>This now allows us to define the impact of the metabolite signalling on the cells in an unbiased manner and to examine the relationship between these changes and polymorphisms associated with human metabolic disease.</gtr:impact><gtr:outcomeId>58754f1d1c39c8.06526032</gtr:outcomeId><gtr:title>Bioinformatic pipeline development for study of metabolic effects on immune cells</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EF14021D-608C-4AC8-8114-D511293F83DB</gtr:id><gtr:title>Structural insights into hedgehog ligand sequestration by the human hedgehog-interacting protein HHIP.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b13fd86e22c120efb853972c740e508f"><gtr:id>b13fd86e22c120efb853972c740e508f</gtr:id><gtr:otherNames>Bishop B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>76A0AC1BDE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F19ED0F-2E8B-40FA-83A6-2BD0945C58CA</gtr:id><gtr:title>Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_12824_24_22184586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5C82495-40D9-4EB0-A5CF-45E0C4025840</gtr:id><gtr:title>OxMaR: open source free software for online minimization and randomization for clinical trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54536433d920f8.82506226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B47E7BBF-AC06-433A-A65D-991584639DD4</gtr:id><gtr:title>Floating-Harbor syndrome and polycystic kidneys associated with SRCAP mutation.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d643f8878cf247e1ade6866cde76dfee"><gtr:id>d643f8878cf247e1ade6866cde76dfee</gtr:id><gtr:otherNames>Reschen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4825</gtr:issn><gtr:outcomeId>pm_12824_24_23165645</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93A53296-3704-4DE3-B9F7-9D81EC41CC95</gtr:id><gtr:title>Expression, purification and crystallization of the human UL16-binding protein ULBP1.</gtr:title><gtr:parentPublicationTitle>Protein expression and purification</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1046-5928</gtr:issn><gtr:outcomeId>FL9H7cUfFNw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA0311A-A64F-444F-9E9A-440232A17DB7</gtr:id><gtr:title>MICA Expression Is Regulated by Cell Adhesion and Contact in a FAK/Src-Dependent Manner.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1393ccf65403303ec5ccfcc2ec249cd"><gtr:id>f1393ccf65403303ec5ccfcc2ec249cd</gtr:id><gtr:otherNames>Moncayo G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>58beb2a5bbdd19.18305250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4711ABF2-3B1C-408B-B552-800FBF781C41</gtr:id><gtr:title>Renal cells activate the platelet receptor CLEC-2 through podoplanin.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dfa75813aa9e1324ba03e32c545cbd7"><gtr:id>7dfa75813aa9e1324ba03e32c545cbd7</gtr:id><gtr:otherNames>Christou CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>F90D8CDFCF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2DEB6BA-F311-46D1-866B-7184CA76A4B6</gtr:id><gtr:title>Genetic and environmental risk factors for atherosclerosis regulate transcription of phosphatase and actin regulating gene PHACTR1.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26b609cef2093a91dd056dcca6758e83"><gtr:id>26b609cef2093a91dd056dcca6758e83</gtr:id><gtr:otherNames>Reschen ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>585d6a8f9ef8a9.43854722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B36B3CA6-54EA-4C6A-BBB4-2C672EEA9A33</gtr:id><gtr:title>Reversible renal impairment caused by thyroid disease.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of urology and nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353c5c1b95245382c0a999053ee2dd94"><gtr:id>353c5c1b95245382c0a999053ee2dd94</gtr:id><gtr:otherNames>Chakera A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-5599</gtr:issn><gtr:outcomeId>nGdXwsh4LFc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AF23EB6-3C87-40C3-96E1-88EF13D24993</gtr:id><gtr:title>A lucky fall? Case report.</gtr:title><gtr:parentPublicationTitle>Transplantation proceedings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353c5c1b95245382c0a999053ee2dd94"><gtr:id>353c5c1b95245382c0a999053ee2dd94</gtr:id><gtr:otherNames>Chakera A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1345</gtr:issn><gtr:outcomeId>B6th19Aso1f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C2CAD6F-6D6C-4CEE-9EBA-7D2BD0C7808B</gtr:id><gtr:title>Regulation of ligands for the activating receptor NKG2D.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28037b28e63ce998c7567e69e5ea6114"><gtr:id>28037b28e63ce998c7567e69e5ea6114</gtr:id><gtr:otherNames>Mistry AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>0FDE8B14A6C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2EACDBA-5FCA-4567-BF22-2178B549BA7A</gtr:id><gtr:title>Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3642ed217efea6e5f217c7abff21b219"><gtr:id>3642ed217efea6e5f217c7abff21b219</gtr:id><gtr:otherNames>Hill NR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58beb2a63d0d55.68655548</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67D1625D-62A9-4163-A6A8-F7F5C4329839</gtr:id><gtr:title>CLEC-2</gtr:title><gtr:parentPublicationTitle>AfCS-Nature Molecule Pages</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/578a0797548c720263c2cedc0af83937"><gtr:id>578a0797548c720263c2cedc0af83937</gtr:id><gtr:otherNames>O'Callaghan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>F56B566B93A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D0C77C8-B44E-40C0-A32D-60511D20412D</gtr:id><gtr:title>Molecular analysis of the interaction of the snake venom rhodocytin with the platelet receptor CLEC-2.</gtr:title><gtr:parentPublicationTitle>Toxins</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2072-6651</gtr:issn><gtr:outcomeId>pm_12824_24_22069753</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB8C2CB2-4FCF-4787-8200-D9B6F823DF2B</gtr:id><gtr:title>CLEC-2 activates Syk through dimerization.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b16d4e1a370fa1ff2f98b536d917d95e"><gtr:id>b16d4e1a370fa1ff2f98b536d917d95e</gtr:id><gtr:otherNames>Hughes CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>dMTNFqq2ZXq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EA79F68-DF12-4253-A104-527D4028898D</gtr:id><gtr:title>The structure of the human allo-ligand HLA-B*3501 in complex with a cytochrome p450 peptide: steric hindrance influences TCR allo-recognition.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd9cdb41b63b19f1798d264e04b29a65"><gtr:id>dd9cdb41b63b19f1798d264e04b29a65</gtr:id><gtr:otherNames>Hourigan CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>609D56F7D97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E39FA7-3A16-428E-BA6B-54C50517F37C</gtr:id><gtr:title>NF-?B regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9a0b3016a7eb7051545856350d7f9af"><gtr:id>d9a0b3016a7eb7051545856350d7f9af</gtr:id><gtr:otherNames>Lin D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_12824_24_22170063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>344E5E18-9FC2-4E3C-8207-C5F35B550640</gtr:id><gtr:title>Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>7C51C4C5FA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF4E985C-A0F1-4BBB-8C54-8EDCE7BF617C</gtr:id><gtr:title>Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>STyDomgTWCt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>404D27A1-DC88-46E3-B1E4-832ABF920F33</gtr:id><gtr:title>Lipid-induced epigenomic changes in human macrophages identify a coronary artery disease-associated variant that regulates PPAP2B Expression through Altered C/EBP-beta binding.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26b609cef2093a91dd056dcca6758e83"><gtr:id>26b609cef2093a91dd056dcca6758e83</gtr:id><gtr:otherNames>Reschen ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>5675e1ba5200e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F162848-8684-423F-9EB0-A7E6D52F1888</gtr:id><gtr:title>Crystallization and X-ray diffraction analysis of human CLEC5A (MDL-1), a dengue virus receptor.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section F, Structural biology and crystallization communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-3091</gtr:issn><gtr:outcomeId>BE5D98BB37D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F9246F1-87AE-4176-BA0B-49A4DF680E13</gtr:id><gtr:title>NKG2D</gtr:title><gtr:parentPublicationTitle>AfCS-Nature Molecule Pages</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/578a0797548c720263c2cedc0af83937"><gtr:id>578a0797548c720263c2cedc0af83937</gtr:id><gtr:otherNames>O'Callaghan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>D6B48C4CF3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0369D3D-B014-4F32-9384-E96D42CEB99C</gtr:id><gtr:title>The Canine POMC Gene, Obesity in Labrador Retrievers and Susceptibility to Diabetes Mellitus.</gtr:title><gtr:parentPublicationTitle>Journal of veterinary internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/173f0b3dfbd00910e6d91068e0b1d1f7"><gtr:id>173f0b3dfbd00910e6d91068e0b1d1f7</gtr:id><gtr:otherNames>Davison LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0891-6640</gtr:issn><gtr:outcomeId>58beb2a60f1f09.33158639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E52FC76-08D5-4564-BB15-BB55EC6C05A3</gtr:id><gtr:title>The hyponatraemic hairdresser: highlighting the differentials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3f67f32276658c8a110202fb443b8bc"><gtr:id>e3f67f32276658c8a110202fb443b8bc</gtr:id><gtr:otherNames>Herrington WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>5AEFFB26264</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9A06AAB-229E-4519-8D55-1A9A383A9EB3</gtr:id><gtr:title>Structure of the fungal beta-glucan-binding immune receptor dectin-1: implications for function.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d99186fe36784093a89ae67dc4a70fcb"><gtr:id>d99186fe36784093a89ae67dc4a70fcb</gtr:id><gtr:otherNames>Brown J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>361C07E78EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E297E9-0BC8-4805-BB7C-8A1F606DD8FB</gtr:id><gtr:title>The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>AB08FBFA7B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1454DE3-86B6-41A5-AA5F-3311F0AB6296</gtr:id><gtr:title>Chronic kidney disease--assessing the impact.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>792BEF07063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC4FDC5E-46E4-460F-8E36-7F61DCDC4179</gtr:id><gtr:title>Analysis of Ebola Virus Entry Into Macrophages.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3efa31466fe53b86d597ffb8798e7c35"><gtr:id>3efa31466fe53b86d597ffb8798e7c35</gtr:id><gtr:otherNames>Dahlmann F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>56df4f23548386.47014071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69BCC667-B674-45E5-ADD2-7D18009166EC</gtr:id><gtr:title>Impact on cardiovascular risk follow-up from a shift to the CKD-EPI formula for eGFR reporting: a cross-sectional population-based primary care study.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d89b29af39acabb8f681abdd983d1e84"><gtr:id>d89b29af39acabb8f681abdd983d1e84</gtr:id><gtr:otherNames>van Gelder VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_12824_24_24071463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A53796A7-FF7E-4B1C-B064-DB87F34986CC</gtr:id><gtr:title>Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations.</gtr:title><gtr:parentPublicationTitle>Human immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e41ce00c0a1e54372a0974e97a87703"><gtr:id>6e41ce00c0a1e54372a0974e97a87703</gtr:id><gtr:otherNames>Antoun A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0198-8859</gtr:issn><gtr:outcomeId>HBtVPbomR1d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5A9CAD8-C383-4C6B-AEC3-8A9F54244777</gtr:id><gtr:title>Defining the T cell antigen proteome of wasp venom.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31d0e3a7e251ddfd1290bf38f51937a3"><gtr:id>31d0e3a7e251ddfd1290bf38f51937a3</gtr:id><gtr:otherNames>Aslam A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0954-7894</gtr:issn><gtr:outcomeId>99F5D75FA0B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03ACF424-A61C-4710-A782-A0E092D531A9</gtr:id><gtr:title>Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b382bbda7fbcdd2e9c740bc2532a40b"><gtr:id>2b382bbda7fbcdd2e9c740bc2532a40b</gtr:id><gtr:otherNames>Alshehri OM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>56df4f238e4f30.20576307</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23CFD35A-5C31-4EA0-ADED-EADBC5D2027D</gtr:id><gtr:title>PeaKDEck: a kernel density estimator-based peak calling program for DNaseI-seq data.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02350a48e449e8768014e8f5ab1453bc"><gtr:id>02350a48e449e8768014e8f5ab1453bc</gtr:id><gtr:otherNames>McCarthy MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>545366344963f2.80640900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6329C505-24DA-4FC2-80CE-E24210DE4B28</gtr:id><gtr:title>Crystallization and X-ray diffraction analysis of human CLEC-2.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section F, Structural biology and crystallization communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1744-3091</gtr:issn><gtr:outcomeId>3DC6914BD85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB47C483-90C5-46E2-AF35-35571EACB40C</gtr:id><gtr:title>Solid-phase plate-reader quantification of specific PCR products by measurement of band-specific ethidium bromide fluorescence.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02350a48e449e8768014e8f5ab1453bc"><gtr:id>02350a48e449e8768014e8f5ab1453bc</gtr:id><gtr:otherNames>McCarthy MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>545364340c0510.51679915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9319D6FE-21B7-4B2C-A751-F0DC2B685AE9</gtr:id><gtr:title>Antigen-specific T cell responses to BK polyomavirus antigens identify functional anti-viral immunity and may help to guide immunosuppression following renal transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/353c5c1b95245382c0a999053ee2dd94"><gtr:id>353c5c1b95245382c0a999053ee2dd94</gtr:id><gtr:otherNames>Chakera A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>P4gZPmnpCQ6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>272BF952-FF29-436F-9F7E-02D899FB542A</gtr:id><gtr:title>Recognition and blocking of innate immunity cells by Candida albicans chitin.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/703b9722e4b369946813a4080a7897c3"><gtr:id>703b9722e4b369946813a4080a7897c3</gtr:id><gtr:otherNames>Mora-Montes HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>p6XrFsSC9Qs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4DA2F4F-C0C9-42D5-9DB3-91EF321C7A17</gtr:id><gtr:title>Purine nucleotide metabolism regulates expression of the human immune ligand MICA.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02350a48e449e8768014e8f5ab1453bc"><gtr:id>02350a48e449e8768014e8f5ab1453bc</gtr:id><gtr:otherNames>McCarthy MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5a575b74bf0730.13123959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6555673-7075-48E7-B67A-4B9492072775</gtr:id><gtr:title>The platelet receptor CLEC-2 is active as a dimer.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36299e25d361f3a506a3aa377ee12437"><gtr:id>36299e25d361f3a506a3aa377ee12437</gtr:id><gtr:otherNames>Watson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>202131E1EF3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28D80965-628F-45D4-BB57-24C541C40891</gtr:id><gtr:title>Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372a17a19f0aa4ad420ec523b27f31e2"><gtr:id>372a17a19f0aa4ad420ec523b27f31e2</gtr:id><gtr:otherNames>Gaulton KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>56df4e5b55a071.72681479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9F456FB-EB56-4438-AF5C-B513144C4787</gtr:id><gtr:title>Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f397129da391a7f73a111f51fff75f0"><gtr:id>0f397129da391a7f73a111f51fff75f0</gtr:id><gtr:otherNames>Morteau O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>jDQjCzs8ekp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D09D166C-89B5-4212-83E0-3D4A9803FA3F</gtr:id><gtr:title>Kidney transplantation--the long term view.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>91386E78675</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A82C08ED-C830-4590-B3E0-BE8216CF9923</gtr:id><gtr:title>Renal manifestations of systemic autoimmune disease: diagnosis and therapy.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1521-6942</gtr:issn><gtr:outcomeId>9D6F8A087CA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CE9344B-AD69-4CC7-AB8C-658F7D03E6E7</gtr:id><gtr:title>Thrombomodulation via CLEC-2 targeting.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4644e284b8085d3fc0e5e374c4b4449"><gtr:id>a4644e284b8085d3fc0e5e374c4b4449</gtr:id><gtr:otherNames>O'Callaghan CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>A804A214A88</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G116/165</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>